Abstract: SA-PO0422
Association Between eGFR and Albuminuria (GA) Staging and Comorbidity Risk in Patients with Diabetic Kidney Disease: A Retrospective Cross-Sectional Study
Session Information
- CKM: Clinical - Epidemiology and Outcomes
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Author
- Tang, Wenbin, Xiangya Hospital Central South University, Changsha, Hunan, China
Background
Diabetic kidney disease (DKD) exhibits considerable clinical heterogeneity, and the relationship between its pathological staging and the burden of comorbidities remains poorly understood. This study aims to investigate the association between GA staging and comorbidity risk in patients with DKD.
Methods
A retrospective cross sectional study was conducted, including 9,252 hospitalized patients with type 2 DKD at Xiangya Hospital, Central South University, from January 2014 to December 2024. GA stages were assigned according to the KDIGO guidelines. Comorbidity was defined as the presence of any of 10 common diseases (hypertension, hyperlipidemia, heart disease, liver disease, cerebrovascular disease, musculoskeletal disease, chronic respiratory disease, peripheral vascular disease, malignancy, and mental/psychological disorders) in addition to type 2 DKD. Complex comorbidity was defined as the presence of ≥3 comorbidities besides type 2 DKD. The age adjusted Charlson Comorbidity Index (CCI) was used to assess overall comorbidity burden, with CCI ≥5 defined as high comorbidity burden. Multivariable regression models, adjusted for relevant confounders, were used to analyze the independent associations between different GA stages and the presence of any comorbidity, complex comorbidity, and high comorbidity burden.
Results
A total of 9,252 DKD patients were included. The three most prevalent comorbidities were hypertension (81.2%), hyperlipidemia (77.2%), and heart disease (47.9%). Overall, 98.5% of patients had at least one comorbidity, the prevalence of complex comorbidity was 61.1%, and the proportion of patients with a high comorbidity burden was 70%. The DKD patients in the very high risk stage had the highest prevalence of complex comorbidity (63.2%). The very high risk stage was an independent risk factor for the presence of any comorbidity (OR=3.51). Both the high risk stage (OR=1.47) and the very high risk stage (OR=1.63) were independent risk factors for complex comorbidity, with risk increasing progressively across stages. The very high risk stage was an independent risk factor for high comorbidity burden (OR=5.91).
Conclusion
Comorbidity profiles and burden evolve dynamically across GA stages. Progression of GA staging is significantly associated with the presence of any comorbidity, complex comorbidity, and high comorbidity burden.
Funding
- Government Support – Non-U.S.